Acute myelogenous leukemia is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal blasts produce white blood cells that do not...
Read More »

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes.  Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® , Rituxan® , and Herceptin® that collectively represented...
Read More »

Scientific and medical advances weren’t the only topic of discussion at the 51st American Society of Hematology Annual Meeting that began over the weekend in New Orleans, LA, as merger and acquisition activity took center stage. Early this morning, Celgene Corporation (CELG) announced the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in...
Read More »

The 51st American Society of Hematology Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA.  This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data...
Read More »

On May 7, 2009, MD Becker Partners LLC hosted its inaugural life sciences roundtable titled “Successful Strategies for Raising Visibility and Capital.” The meeting brought together experts from leading investment banks, life sciences companies, venture investment groups, and the media to discuss the issues surrounding effective two-way communication between a company, the financial community,...
Read More »